The EBDC 2016 will examine topics such as trends in Immuno-oncology, cures for neurologic diseases as well as challenges and advantages in R&D of orphan medicinal products. We will also look at the financial landscape in Europe.
We will again offer this partnering website and platform, allowing you to meet privately with international decision makers from the biotech and pharmaceutical sectors, as well as other life sciences industry suppliers.
The conference programme will include company presentation of innovative biotech firms presenting their research, products and technologies to the other conference participants and investors.
The EBDC is an annual event that brings leading decision makers from international pharmaceutical companies and European biotech firms together with representatives of private equity and venture capital companies (see list of attending companies). The EBDC provides a forum for making contacts and discussing topics and trends of relevance to the market. The conference is attended by CEOs, managing directors and senior business development managers.
Representatives of the following companies have already confirmed their attendance:
[iito] Business Intelligence, a2m Pharma, Aarhus University, Abviris Deutschland, AC Immune, Ad-O-Lytics, aescuvest, Aeterna Zentaris, Affiris, AiCuris Anti-infective Cures, Alexion, apceth, Apogenix, Aptuit, Atriva Therapeutics, BAND, Bayer Pharma, Bayerische Patentallianz, BCNP, Beacon Cure, BEROCEUTICA, BioMedPartners, BioSpring, Bone Therapeutics, Carbogen Amcis, Cellab, Cellestia Biotech, Cell Therapy, Constares, cpo - cellular phenomics & oncology, Creathor Venture Management, Cyprumed, Cytolon Digital Health, Dentons Europe, Deutsches Krebsforschungszentrum (DKFZ), EBE, emovis home care visits, European Investment Bank, FGK Clinical Trials, Fraunhofer IME, Fresenius Kabi Deutschland, Galmed Pharmaceuticals, Heidelberg Pharma, Hessen Trade & Invest, Hummingbird Diagnostics, inhive, Janssen-Cilag, , Lipotype, Lonza, MacDougall Biomedical Communications, Max-Planck-Innovation, Medigene, Menarini Biotech, Merck, Miltenyi Biotec, MSD, NDA Regulatory, Novartis Pharma, oncgnostics, Orla Protein Technologies, origenis, Pfizer, Phenex Pharmaceuticals, PKCie Management Consultants, QPS,Probiodrug, Procera Pharmaceuticals, PROGEN Biotechnik, Protagen Protein Services, Provitro, R-Biopharm AG, Rigontec, Roche, RTC, Sanofi, SAP, Science4Life, Sonovum, SpinDiag, Spiral Therapeutics, Sulfotools, SunstoneCapital, TauRx, Technologiepark Heidelberg, TransMIT, UK Department for International Trade, Vita 34, XL-protein, Zedira